XSHG
600518
Market cap2.75bUSD
Oct 09, Last price
1.35CNY
1D
1.50%
1Q
5.47%
Jan 2017
-92.44%
IPO
18.36%
Name
Kangmei Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical institution resources, smart pharmacies, OTC retail, chain drug stores, direct sales, medical e-commerce, mobile medical care, etc. Kangmei Pharmaceutical Co., Ltd. was founded in 1997 and is based in Shenzhen, China.
Key people
Zhijian Lai
Chairman of the Board · since 2022
Guibo Gong
Chief Financial Officer, Deputy General Manager · since 2022
Qiyun Chen
Deputy General Manager · since 2021
Zezheng He
Deputy General Manager, Chief Human Resources and Administration Officer · since 2022
Xinquan Liu
Deputy General Manager · since 2022
Zebin Li
Assistant to the General Manager · since 2022
Jinjin Zhang
Assistant to the General Manager · since 2025
Yunfeng Zhou
Chief Compliance Officer, Deputy General Manager, Secretary of the Board, Director · since 2025
Weizhong Huang
Director · since 2025
Jun Liang
Director · since 2022
Guoxiong Ou
General Manager, Director · since 2025
Huayue Xia
Director · since 2024
Xiaoping Lai
Independent Director · since 2020
Hui Lin
Independent Director · since 2025
Tao Luo
Independent Director · since 2022
Independent Director · since 2025
Headquarters & legal address
广东省普宁市流沙揭神路东侧
揭阳市, GD 100000
CN
揭阳市, GD 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||